研究单位：[1]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[2]Shanghai Miracogen Inc.[3]Anhui provincial Cancer Hospital,Hefei,Anhui,China,230031[4]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[5]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100000[6]Beijing hospital,Beijing,Beijing,China,100005[7]Beijing Chao-Yang Hospital，Capital Medical University,Beijing,Beijing,China,100020[8]The Fifth Medical Center of the PLA,Beijing,Beijing,China,100039[9]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400030[10]Army Medical Center of PLA,Chongqing,Chongqing,China,400042[11]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[12]SUN Yat-sen university Cancer center,Guangzhou,Guangdong,China,510060[13]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510120[14]ShenZhen Luohu People's Hospital,ShenZhen,Guangdong,China,518005[15]The Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai,Guangdong,China,519000[16]Liuzhou People's Hospital,Liuzhou,Guangxi,China,545026[17]Haerbin medical university cancer hospital,Haerbin,Heilongjiang,China,150081[18]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[19]Union hospital tongji medical college huazhong univerity ofscience and technology,Wuhan,Hubei,China,430022[20]Tongji Hospital,Wuhan,Hubei,China,430030[21]Xiangya hospital central south university,Changsha,Hunan,China,410008[22]The Affiliated Cancer Hospital of Xiangya School of Medicine(Hunan Cancer Hospital ),Changsha,Hunan,China,410031[23]Nantong Tumor Hospital,Nantong,Jiangsu,China,226006[24]The First Hospital of Jilin University,Changchun,Jilin,China,130061[25]JiLinGuoWen Hospital,Siping,Jilin,China,136199[26]Liaoning Cancer hospital,Shenyang,Liaoning,China,110042[27]Qinghai University Affiliated Hospital,Xining,Qinghai,China,810012[28]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[29]Rui jin hospital,Shanghai,Shanghai,China,200025[30]Zhongshan Hospital Affiliated to Fudan University,Shanghai,Shanghai,China,200125[31]Changhai Hospital,Shanghai,Shanghai,China,200433[32]First Affiliated Hospital of Xi'an Jiaotong University,Xian,Shanxi,China,710061[33]Sichuan provincial people's hospital,Chengdu,Sichuan,China,610072[34]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300181[35]The Second Hospital of Tianjin Medical University,Tianjin,Tianjin,China,300211[36]The second Affiliated Hospital Zhejiang University School of Medical,Hangzhou,Zhejiang,China,310003[37]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Hangzhou,Zhejiang,China,310005[38]The 1'Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China,325015
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive unresectable locally advanced or metastatic urothelium cancer.
